Kristie L. Kahl

The amount of preventative medicines given during hospital admission may be associated with an increased amount prescribed at discharge – resulting in higher costs and an increased risk for drug-drug interactions in patients with advanced lung cancer.

In the first such clinical trial in the United States, researchers will evaluate focused ultrasound to breach the blood-brain barrier

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.

In this week’s special edition of CURE Talks Cancer, we spoke with Bravo TV’s “Real Housewives of Beverly Hills” star Camille Grammer about her experience with uterine cancer, and the advocacy work she does for “below the belt” cancers.

Alejandra Campoverdi shares her experience with having a BRCA2 mutation and explains how the Well Women Coalition is helping to start the conversation among women of color across the country.

Eleven years ago, Stephanie Hosford received two pieces of life-changing news within the span of three days: she was diagnosed with triple-negative breast cancer and she found out she was pregnant – all while going through an adoption process at the same time.

In this special edition of the CURE Talks Cancer podcast, we kick off National Hereditary Breast and Ovarian Cancer Week and Previvor Day.

Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.

A recent study from St. Jude Children’s Hospital found that more than half of adults who survived pediatric central nervous system tumors failed to achieve independence as adults.

The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory and anxiety.

Patient-caregiver communities focused on non-small cell lung cancer with genomic alterations offer support, awareness and education to help accelerate research in this space.

“Key brain regions that we know are typically involved in autobiographical memory formation and retrieval, especially the hippocampus, are located quite far from the primary tumor bed, and thus far from the site of focal radiation,” Sekeres, who is director of the Sekeres Memory Laboratory at Baylor University, said in an interview with CURE.

In this episode of CURE Talks Cancer, we spoke with Elizabeth Langdon, vice president of strategic communications and development at the Head and Neck Cancer Alliance, about how the organization helps to raise awareness for the prevention, early detection and research of head and neck cancer.

A recent study showed that socioeconomic status may explain racial and ethnic disparities found among childhood cancer survivors of certain cancers.

Nicholas J. Vogelzang, M.D., FASCO, FACP, has seen cancer through a variety of lenses – from oncologist to patient as well as caregiver – giving him a different perspective than most.

A study published in Blood demonstrated the significant disparities found between insurance status and survival outcomes in patients of all ages with follicular lymphoma.

The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

In this week’s episode of CURE Talks Cancer, we speak with Rose Gerber, director of patient advocacy at CPAN, about her experience with breast cancer, how she became an advocate and how her journey helped her to see beyond the cancer experience.

The Food and Drug Administration (FDA) granted priority review to a new supplemental biologics license application for Keytruda (pembrolizumab) to treat adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to Merck, the agent’s manufacturer.

Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.

In this week’s episode, we speak with author and avid patient advocate Shannon Pulaski about her new efforts to help empower children to learn about their family’s health history.

A recent survey of physicians revealed that 17 percent of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.

In a recent study, researchers from the American Cancer Society found that patients who reported higher satisfaction with their physician’s communication also had better health outcomes at lower costs.

In this special edition of CURE Talks Cancer, we spoke with NFL Hall of Fame quarterback Jim Kelly about his experience with head and neck cancer, and the humbling experience of winning the Jimmy V award for Perseverance at this year’s ESPY Awards.

CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.

Talazoparib reduced the risk for disease progression or death by 46 percent and improved quality of life compared with chemotherapy in a subgroup of women with breast cancer, according to the phase 3 EMBRACA trial results.

CAR-T cell therapy has been showing promising in treating children with acute lymphoblastic leukemia, but it can come with significant toxicities.

In this week’s episode of CURE Talks Cancer, we spoke with Ethan Hawes about his experience as a 22-year-old diagnosed with multiple myeloma, and his advice for others going through a similar journey.